Report of the Institute of Medicine Committee on the Efficacy and Safety of Halcion.
Bunney
W E
WE
Azarnoff
D L
DL
Brown
B W
BW
Cancro
R
R
Gibbons
R D
RD
Gillin
J C
JC
Hullett
S
S
Killam
K F
KF
Kupfer
D J
DJ
Krystal
J H
JH
Stolley
P D
PD
French
G S
GS
Pope
A M
AM
D016907:Adverse Drug Reaction Reporting Systems; D002908:Chronic Disease; D017277:Drug Approval; D004341:Drug Evaluation / Q000592:standards; D005069:Evaluation Studies as Topic; D006801:Humans; D006993:Hypnotics and Sedatives / Q000009:adverse effects* / Q000627:therapeutic use; D015969:National Academies of Science, Engineering, and Medicine, U.S., Health and Medicine Division; D015995:Prevalence; D011358:Product Surveillance, Postmarketing; D011367:Professional Staff Committees; D016032:Randomized Controlled Trials as Topic / Q000592:standards; D012107:Research Design / Q000592:standards; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy* / Q000453:epidemiology; D014229:Triazolam / Q000009:adverse effects* / Q000627:therapeutic use; D014481:United States / Q000453:epidemiology; D014486:United States Food and Drug Administration
D006993:Hypnotics and Sedatives; D014229:Triazolam